Welcome to the course on Emerging Concepts in Anticancer Drug Development and Clinical Pharmacology (ECADDCP), to be held in Amsterdam on 8 and 9 November, 2018.
The complex landscape of oncology drug development is moving away from traditional dosing based on toxicity. As conventional strategies are becoming obsolete, it is vital for industry professional to keep abreast of the novel approaches and modern tools that are becoming available in the development of anticancer drugs.
Developed by the award winning and honorary fellow of the American College of Clinical Pharmacology Mark J. Ratain, MD, this advanced course will focus on new directions in drug development strategies and will include discussion of drug combinations, immunotherapy, and oral dosing regimens. Mathematical approaches will be introduced, including studies on pharmacodynamic biomarkers and pharmacometric modelling of efficacy and toxicity.
This ambitious program will be delivered by the top oncology experts and thought leaders in an intimate and flexible setting, with generous time allocated to audience participation and availability of confidential sessions for company groups. A limited enrolment policy will also be put in place and will provide optimal networking opportunities and direct dialogue in a relaxed, informal, yet highly productive setting. This is a unique opportunity for oncologists and clinical pharmacologists involved in early clinical trials to optimize their professional performance and practice in an ever-changing and antagonistic landscape.